James E. Tisdale
1988 PharmD, State University of New York at Buffalo
1984 Pharmacy Practice Residency, University of Manitoba Health Sciences Center, Winnipeg, Manitoba, Canada
1983 BScPharm, University of Manitoba, Winnipeg, Manitoba, Canada
I am a clinical/translational scientist with over 30 years of experience in investigations in the areas of cardiovascular pharmacology, pharmacotherapy, and translational research. The focus of my research program is prevention and management of atrial fibrillation and drug-induced arrhtyhmias, particularly QT interval prolongation and torsades de pointes. I have extensive experience in basic science and clinical studies, including investigations of sex differences in arrhythmias and the influence of sex hormones on ventricular repolarization and arrhythmias. I led a team that developed a risk score for QT interval prolongation in hospitalized patients in cardiac intensive care units (which has come to be known as the Tisdale score), that is used commonly worldwide. We have investigated methods of prevention of postoperative atrial fibrillation. A number of our studies are cited in widely used treatment guidelines. We have completed numerous investigations of the administration of sex hormones (progesterone and testosterone) as drugs for attenuation of drug-induced QT interval lengthening. We are also investigating the etiology of and risk factors for palpitations in peri- and postmenopausal women, as well as the efficacy of inhibition of small conductance calcium-activated potassium current for management of atrial fibrillation.
Service and Engagement
Chair, Board of Directors, Pharmacotherapy Publications, Inc (2020-present)
President, American College of Clinical Pharmacy, 2009-2010.
Member, Board of Regents, American College of Clinical Pharmacy (2001-2004 and 2008-2011)
Chair, Clinical Sciences Section, Academy of Pharmaceutical Research & Science, American Pharmacists Association (2008-2009)
Scientific Editor, Pharmacotherapy (2015 - present)
Consulting Editor, Cardiology, Pharmacological Research (2020-present)
Member, Editorial Board, Trends in Cardiovascular Medicine (2017-present)
Member, Board of Directors, AZCERT (2017-present)
Member, Scientific Advisory Board, QT drugs list, www.crediblemeds.org
Member, Clinical Pharmacology Committee, American Heart Association (2014-2018)
Member, Electrophysiology Section Leadership Council, American College of Cardiology (2017 - 2023)
PHRM 84500, Integrated Pharmacotherapy III
PHRM 820 Pharmacy Skills Laboratory I
PHRM 821 Pharmacy Skills Laboratory II
PHRM 860 Pharmacy Skills Laboratory V
CLPH 69000-02 Cardiac Ion Channels and Clinical Electrophysiology
Honors and Credentials
Board Certified Pharmacotherapy Specialist (since 1992)
Fellow, American College of Clinical Pharmacy (FCCP)
Fellow, American Pharmacists Association (FAPhA)
Fellow and Distinguished Practitioner, National Academics of Practice (FNAP)
Fellow, American Heart Association (FAHA)
Fellow, American College of Cardiology (FACC)
Faculty Preceptor of the Year Award, College of Pharmacy, Purdue University (2005)
Dr. Aziz Outstanding Teacher of the Year Award, College of Pharmacy, Purdue University (2013)
Establishment of the annual Tisdale Pharmacy Professionalism Award by the Indiana College of Clinical Pharmacy (2011)
Outstanding Paper of the Year Award, Cardiology Practice and Research Network, American College of Clinical Pharmacy (2015)
Russell R. Miller Award, American College of Clinical Pharmacy (ACCP), awarded for sustained contributions to the literature (2017)
Service Award, Cardiology Practice and Reseach Network, ACCP (2022)
Won 9 teaching awards in 12 years at Wayne State University
Selected grant funding:
Inhibition of Small Conductance Calcium-Activated Potassium Current: A New Therapeutic Approach for Atrial Fibrillation (22TPA964193). Transformational Project Award, American Heart Association, July 1, 2022 - June 30, 2025 (PI)
Risk of Drug-Induced QT Interval Prolongation and Associated Proarrhythmia in Patients with Heart Failure with Preserved Ejection Fraction. Pilot Funding for Research Use of Core Facilities, Indiana Clinical & Translational Sciences Institute (CTSI), January 15, 2021 - January 14, 2023 (PI)
Novel Approaches for Minimizing Drug-Induced QT Interval Lengthening (1R01HL153114). National Heart, Lung & Blood Institute, August 1, 2020 - July 31, 2025 (PI).
Phenotypic Characterization of Menopausal Palpitations. Collaboration in Translational Research grant, Indiana CTSI, May 1, 2020 - April 30, 2022 (no-cost extension through April 30, 2023) (co-PI with Dr. Janet Carpenter)
Reducing the Risk of Drug-Induced QT Interval Lengthening in Women (18TPA34170523). Transformational Project Award, American Heart Association, July 1, 2018 - June 30, 2021 (nocost extension through March 15, 2023) (PI)
Influence of Testosterone Administration on Drug-Induced QT Interval Prolongation and Torsades de Pointes (15GRNT24470168). Grant-in-Aid, American Heart Association, July 1, 2015 - June 30, 2017 (PI).
Influence of progesterone administration on drug-induced QT interval prolongation and torsades de pointes (12GRNT12060187). Grant-in-Aid, American Heart Association, July 1, 2012 - June 30, 2014 (PI).
Administration and Committee Work
Interim Head, Department of Pharmacy Practice, Purdue University (2012-2014)
1. Tan MS, Heise CW, Gallo T, Tisdale JE, Woosley RL, Antonescu CC, Gephart SM, Malone DC. Relationship between a risk score for QT interval prolongation and mortality across rural and urban inpatient facilities. J Electrocardiol 2023;77:4-9.
2. Carpenter JS, Cortés YI, Tisdale JE, Sheng Y, Jackson EA, Barinas-Mitchell E, Thurston RC. Palpitations across the menopause transition in SWAN: trajectories, characteristics and associations with subclinical cardiovascular disease. Menopause 2023;30:18-27.
3. Gallo T, Heise CW, Woosley RL, Tisdale JE, Antonescu CC, Gephart SM, Malone DC. Clinician satisfaction with advanced clinical decision support to reduce the risk of torsades de pointes. J Patient Saf 2023;77:4-9.
4. Tisdale JE (ed). Torsades de pointes. London; Elsevier: 2022.
5. Ueoka A, Sung YL, Liu X, Rosenberg C, Chen Z, Everett TH, Rubart M,Tisdale JE, Chen PS. Testosterone does not shorten action potential duration in Langendorff perfused rabbit ventricles. Heart Rhythm 2022;19:1864-1871.
6. Rowe EJ, Shugg T, Ly RC, Philips S, Rosenman MB, Callaghan JT, Radovich M, Overholser BR, Schneider BP, Tisdale JE, Skaar TC. Association of QT interval-prolonging drugs with clinical trial eligibility in patients with advanced cancer. Front Cardiovasc Med 2022;December 15: doi:.org/10.3389/fcvm.2022.894623.
7. Mar PL, Gopinathannair R, Gengler BE, Chung MK, Perez A, Dukes J, Ezekowitz MD, Lakkireddy D, Lip GYH, Miletello M, Noseworthy PA, Reiffel J, Tisdale JE, Olshansky B. Drug interactions affecting oral anticoagulant use. Circ Arrhythm Electrophysiol 2022;15:e007956.
8. Gallo T, Heise CW, Woosley RL, Tisdale JE, Tan MS, Gephart SM, Antonescu CC, Malone DC. Clinician responses to a clinical decision support advisory for high risk of torsades de pointes. J Am Heart Assoc 2022;11:e024338.
9. Mar PL, Horbal P, Chung MK, Dukes JW, Ezekowitz M, Lakkireddy D, Lip GYH, Miletello M, Noseworthy PA, Reiffel JA,Tisdale JE, Olshansky B, Gopinathannair R. Drug interactions affecting antiarrhythmic drug use. Circ Arrhythm Electrophysiol 2022;15:e007955.
10. Carpenter JS, Tisdale JE, Larson JC, Sheng Y, Chen CX, Von Ah D, Kovacs R, Reed SD, Thurston RC, Guthrie KA. MsFLASH analysis of diurnal salivary cortisol and palpitations in peri- and postmenopausal women. Menopause 2022;29;144-150.
11. Titus-Lay EN, Jaynes HA, Tomaselli Muensterman E, Ott CA, Walroth TA, Williams G, Moe PR, Wilbrandt M, Tisdale JE. Accuracy of a single-lead mobile smartphone electrocardiogram for QT interval measurement in patients undergoing maintenance methadone therapy. Pharmacotherapy 2021;41:494-500.
12. Muensterman ET, Jaynes HA, Sowinski KM, Overholser BR, Shen C, Kovacs RJ, Tisdale JE. Transdermal testosterone attenuates drug-induced lengthening of both early and late ventricular repolarization in older men. Clin Pharmacol Ther 2021;109:1499-1504.
13. Carpenter JS, Tisdale JE, Chen CX, Kovacs R, Larson JC, Guthrie KA, Ensrud KE, Newton KM, LaCroix AZ. A Menopause Strategies-Finding Lasting Answers for Symptoms and Health (MsFLASH) investigation of self-reported menopausal palpitation distress. J Women’s Health 2021;30:533-538.
14. Titus-Lay EN, Jaynes HA, Muensterman ET, Walroth TA, Ott CA, Desta Z, Williams G, Moe PR, Wilbrandt M, Tisdale JE. Methadone-associated QT interval prolongation in patients undergoing maintenance therapy in an urban opioid treatment program. Pharmacotherapy 2021;41:238-246.
15. Tisdale JE, Chung MK, Campbell KB, Hammadah M, Joglar JA, Leclerc J, Rajagopalan B; on behalf of the American Heart Association Clinical Pharmacology Committee of the Council on Clinical Cardiology and Council on Cardiovascular and Stroke Nursing. Drug-induced arrhythmias: a scientific statement from the American Heart Association. Circulation 2020;142:e214-e243.
16. Tisdale JE, Jaynes HA, Overholser BR, Sowinski KM, Fisch MD, Rodgers JE, Aldemerdash A, Hsu C-C, Wang N, Muensterman ET, Rao V, Kovacs RJ. Enhanced response to drug-induced QT interval lengthening in patients with heart failure with preserved ejection fraction. J Cardiac Fail 2020;26:781-785.
17. Bauman JL, Tisdale JE. Chloroquine and hydroxychloroquine in the era of SARS – CoV2: caution on their cardiac toxicity. Pharmacotherapy 2020;40:387-388.
18. Muensterman ET, Jaynes HA, Sowinski KM, Overholser BR, Shen C, Kovacs RJ, Tisdale JE. Effect of transdermal testosterone and oral progesterone on drug-induced QT interval lengthening in older men: a randomized, double-blind placebo-controlled crossover-design study. Circulation 2019;140:1127-1129.
19. Tisdale JE, Jaynes HA, Overholser BR, Sowinski KM, Kovacs RJ. Progesterone pretreatment reduces the incidence of drug-induced torsades de pointes in atrioventricular node-ablated isolated perfused rabbit hearts. J Cardiovasc Electrophysiol 2019;30:941-949.
20. Tisdale JE, Miller DA (eds). Drug-Induced Diseases: Prevention, Detection and Management, 3rd ed. Bethesda; American Society of Health-System Pharmacists: 2018
21. Tisdale JE, Jaynes HA, Overholser BR, Sowinski KM, Flockhart DA, Kovacs RJ. Influence of oral progesterone administration on drug-induced QT interval lengthening. A randomized, placebo-controlled crossover trial. JACC Clin Electrophysiol 2016;2:765-774.
22. Tisdale JE, Jaynes HA, Kingery JR, Overholser BR, Mourad NA, Trujillo TN, Kovacs RJ. Effectiveness of a clinical decision support system for reducing the risk of QT interval prolongation in hospitalized patients. Circ Cardiovasc Qual Outcomes 2014;7:381-390.
23. Tisdale JE, Jaynes HA, Kingery JR, Mourad NA, Trujillo TN, Overholser BR, Kovacs RJ. Development and validation of a risk score to predict QT inverval prolongation in hospitalized patients. Circ Cardiovasc Qual Outcomes 2013;6:479-487.
24. Tisdale JE, Wroblewski HA, Wall DS, Rieger KM, Hammoud ZT, Young JV, Kesler KA. A randomized, controlled study of amiodarone for prevention of atrial fibrillation after transthoracic esophagectomy. J Thorac Cardiovasc Surg 2010;140:45-51.
25. Tisdale JE, Wroblewski HA, Wall DS, Rieger KM, Hammoud ZT, Young JV, Kesler KA. A randomized trial evaluating amiodarone for prevention of atrial fibrillation after pulmonary resection. Ann Thorac Surg 2009;88:886-895.
26. Amankwa K, Krishnan CK, Tisdale JE. Torsades de pointes associated with fluoroquinolones. Importance of concomitant risk factors. Clin Pharmacol Ther 2004;75:242-7.
27. Sharma ND, Rosman HS, Padhi ID, Tisdale JE. Torsades de pointes associated with intravenous haloperidol in critically ill patients. Am J Cardiol 1998;81:238-240.